![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 6
Zeitschriftenartikel
Harbeck, Nadia; Burstein, Harold J.; Hurvitz, Sara A.; Johnston, Stephen und Vidal, Gregory A.
(2022):
A look at current and potential treatment approaches for hormone receptor-positive, HER2-negative early breast cancer.
In: Cancer, Bd. 128: S. 2209-2223
[PDF, 354kB]
Hurvitz, Sara A.; Bachelot, Thomas; Bianchini, Giampaolo; Harbeck, Nadia; Loi, Sherene; Park, Yeon Hee; Prat, Aleix; Gilham, Leslie; Boulet, Thomas; Gochitashvili, Nino; Monturus, Estefania; Lambertini, Chiara; Nyawira, Beatrice; Knott, Adam; Restuccia, Eleonora und Schmid, Peter
(2022):
ASTEFANIA: adjuvant ado-trastuzumab emtansine and atezolizumab for high-risk, HER2-positive breast cancer.
In: Future Oncology, Bd. 18, Nr. 32: S. 3563-3572
Onesti, Concetta Elisa; Rugo, Hope S.; Generali, Daniele; Peeters, Marc; Zaman, Khalil; Wildiers, Hans; Harbeck, Nadia; Martin, Miguel; Cristofanilli, Massimo; Cortes, Javier; Tjan-Heijnen, Vivianne; Hurvitz, Sara A.; Berchem, Guy; Tagliamento, Marco; Campone, Mario; Bartsch, Rupert; De Placido, Sabino; Puglisi, Fabio; Rottey, Sylvie; Müller, Volkmar; Ruhstaller, Thomas; Machiels, Jean-Pascal; Conte, PierFranco; Awada, Ahmad und Jerusalem, Guy
(2020):
Oncological care organisation during COVID-19 outbreak.
In: Esmo Open, Bd. 5, Nr. 4, e000853
Hurvitz, Sara A.; Martin, Miguel; Jung, Kyung Hae; Huang, Chiun-Sheng; Harbeck, Nadia; Valero, Vicente; Stroyakovskiy, Daniil; Wildiers, Hans; Campone, Mario; Boileau, Jean-Francois; Fasching, Peter A.; Afenjar, Karen; Spera, Gonzalo; Lopez-Valverde, Vanesa; Song, Chunyan; Trask, Peter; Boulet, Thomas; Sparano, Joseph A.; Symmans, W. Fraser; Thompson, Alastair M. und Slamon, Dennis
(2019):
Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study.
In: Journal of Clinical Oncology, Bd. 37, Nr. 25
Tripathy, Debu; Im, Seock-Ah; Colleoni, Marco; Franke, Fabio; Bardia, Aditya; Harbeck, Nadia; Hurvitz, Sara A.; Chow, Louis; Sohn, Joohyuk; Lee, Keun Seok; Campos-Gomez, Saul; Vazquez, Rafael Villanueva; Jung, Kyung Hae; Babu, K. Govind; Wheatley-Price, Paul; Laurentiis, Michelino de; Im, Young-Hyuck; Kümmel, Sherko; El-Saghir, Nagi; Liu, Mei-Ching; Carlson, Gary; Hughes, Gareth; Diaz-Padilla, Ivan; Germa, Caroline; Hirawat, Samit und Lu, Yen-Shen
(2018):
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.
In: Lancet Oncology, Bd. 19, Nr. 7: S. 904-915
Hurvitz, Sara A.; Martin, Miguel; Symmans, W. Fraser; Jung, Kyung Hae; Huang, Chiun-Sheng; Thompson, Alastair M.; Harbeck, Nadia; Valero, Vicente; Stroyakovskiy, Daniil; Wildiers, Hans; Campone, Mario; Boileau, Jean-Francois; Beckmann, Matthias W.; Afenjar, Karen; Fresco, Rodrigo; Helms, Hans-Joachim; Xu, Jin; Lin, Yvonne G.; Sparano, Joseph und Slamon, Dennis
(2018):
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
In: Lancet Oncology, Bd. 19, Nr. 1: S. 115-126